Jenkinson, Claire, Elliott, Victoria, Evans, Anthony, Oldfield, Lucy, O'Brien, Darragh, Apostolidou, Sophia, Gentry-Maharaj, Aleksandra, Fourkala, Evangelia- O., Jacobs, Ian, Menon, Usha, Cox, Trevor, Campbell, Fiona, Tuveson, David, Greenhalf, William, Sutton, Robert, Pereira, Stephen, Timms, John, Neoptolemos, John, Costello, Eithne (June 2015) Decreased serum thrombospondin-1 levels in pancreatic ductal adenocarcinoma patients: an early indicator of disease or diabetes mellitus development? Pancreatology, 15 (3, Sup). S28. ISSN 1424-3903
Abstract
Introduction: Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal adenocarcinoma (PDAC) could improve outcome. Aims: Serum protein profiles in patients with pre-clinical disease and at diagnosis were investigated. Patients & methods: Serum from cases up to 4 years prior to diagnosis of PDAC and controls enrolled on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS, n=174) were studied, alongside samples from patients diagnosed with PDAC, chronic pancreatitis, benign biliary disease and from healthy subjects (n=199). Isobaric tags for relative and absolute quantification (iTRAQ) enabled comparisons of pooled serum from a test set (n=150). Validation was undertaken using multiple reaction monitoring (MRM) and/or western blotting in all 373 human samples and in a KPC mouse model. Results: iTRAQ identified thrombospondin-1 (TSP-1) as down-regulated pre-clinically and in diagnosed patients. MRM confirmed significant down-regulation of TSP-1 up to 24 months prior to diagnosis. A combination of TSP-1 and CA19-9 (AUC= 0.86), significantly outperformed both markers alone (0.69 & 0.77 respectively). TSP-1 was also decreased in PDAC patients compared to healthy controls (P<0.05), patients with benign biliary obstruction (P<0.01) and in serum of KPC mice with PDAC. Low levels of TSP-1 correlated with poorer survival pre-clinically (P<0.05) and at diagnosis (P<0.02). Reduced TSP-1 levels were observed in PDAC patients with a confirmed diabetes mellitus (P<0.04). The decrease in TSP-1 compared to healthy controls was only observed in PDAC patients with diabetes (P<0.009). Conclusion: Circulating TSP-1 levels decrease during the development of PDAC. The influence of diabetes mellitus on biomarker behavior should be considered in future studies.
| Item Type: | Paper |
|---|---|
| Additional Information: | Meeting Abstract |
| Subjects: | diseases & disorders > nutritional and metabolic diseases > diabetes Publication Type > Meeting Abstract diseases & disorders > cancer > cancer types > pancreatic cancer |
| CSHL Authors: | |
| Communities: | CSHL labs > Tuveson lab |
| Depositing User: | Matt Covey |
| Date: | June 2015 |
| Date Deposited: | 12 Jun 2015 16:59 |
| Last Modified: | 05 Feb 2018 21:27 |
| URI: | https://repository.cshl.edu/id/eprint/31579 |
Actions (login required)
 |
Administrator's edit/view item |